Last reviewed · How we verify
meningococcal B rLP2086 vaccine candidate
meningococcal B rLP2086 vaccine candidate is a Biologic drug developed by Wyeth is now a wholly owned subsidiary of Pfizer. It is currently in Phase 1 development.
At a glance
| Generic name | meningococcal B rLP2086 vaccine candidate |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- meningococcal B rLP2086 vaccine candidate CI brief — competitive landscape report
- meningococcal B rLP2086 vaccine candidate updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI
Frequently asked questions about meningococcal B rLP2086 vaccine candidate
What is meningococcal B rLP2086 vaccine candidate?
meningococcal B rLP2086 vaccine candidate is a Biologic drug developed by Wyeth is now a wholly owned subsidiary of Pfizer.
Who makes meningococcal B rLP2086 vaccine candidate?
meningococcal B rLP2086 vaccine candidate is developed by Wyeth is now a wholly owned subsidiary of Pfizer (see full Wyeth is now a wholly owned subsidiary of Pfizer pipeline at /company/wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer).
What development phase is meningococcal B rLP2086 vaccine candidate in?
meningococcal B rLP2086 vaccine candidate is in Phase 1.